Tokyo, Japan

Takehide Kimura

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignees: Kyowa Medex Co., Ltd., Kyoto University. Active years: 2015-2018.


% Patents Active = 66.7


 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015-2018

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Takehide Kimura: Innovator in Glycated Hemoglobin Measurement

Introduction

Takehide Kimura is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of medical diagnostics, particularly in the measurement of glycated hemoglobin. With a total of 3 patents to his name, Kimura's work is instrumental in diagnosing lifestyle-related diseases such as diabetes mellitus.

Latest Patents

Kimura's latest patents include innovative methods for measuring glycated hemoglobin in samples. One method involves directly oxidizing glycated hemoglobin and measuring the substance produced or consumed by the oxidation. Another method utilizes an enzyme for the same purpose, enhancing the accuracy of the measurement. These inventions are crucial for diagnosing conditions related to lifestyle diseases.

Career Highlights

Throughout his career, Takehide Kimura has worked with notable organizations such as Kyowa Medex Co., Ltd. and Kyoto University. His experience in these institutions has allowed him to develop and refine his innovative methods for glycated hemoglobin measurement.

Collaborations

Kimura has collaborated with esteemed colleagues, including Noriyuki Ogawa and Fumi Umehara. Their joint efforts have contributed to advancements in the field of medical diagnostics.

Conclusion

Takehide Kimura's contributions to the measurement of glycated hemoglobin have made a significant impact on the diagnosis of diabetes and other lifestyle-related diseases. His innovative methods and collaborations continue to influence the medical field positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…